---
title: "JW Therapeutics Advances with In-House Lentiviral Vector for Carteyva®"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260407644.md"
description: "JW Therapeutics has announced that the National Medical Products Administration of China has accepted its supplementary application for Carteyva®, now utilizing an in-house lentiviral vector. This advancement ensures a stable supply, reduces costs, and enhances the product's commercial value, strengthening the company's position in the cell therapy market. The current analyst rating for JW Therapeutics (HK:2126) is a Hold with a price target of HK$6.00."
datetime: "2025-10-09T09:09:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260407644.md)
  - [en](https://longbridge.com/en/news/260407644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260407644.md)
---

# JW Therapeutics Advances with In-House Lentiviral Vector for Carteyva®

JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has issued an announcement.

JW Therapeutics announced that the National Medical Products Administration of China has accepted its post-marketing supplementary application for Carteyva®, which now uses an in-house produced lentiviral vector. This development is significant as it ensures a stable supply and reduces costs, enhancing the commercial value of Carteyva® and strengthening JW Therapeutics’ position in the competitive cell therapy market.

The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.

**More about JW (Cayman) Therapeutics Co. Ltd.**

JW (Cayman) Therapeutics Co. Ltd is an independent and innovative biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products. The company is known for its CAR-T cell immunotherapy product, Carteyva®, which is approved for multiple oncology indications in China.

**Average Trading Volume:** 4,988,280

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$1.94B

Learn more about 2126 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02126.HK](https://longbridge.com/en/quote/02126.HK.md)

## Related News & Research

- [Only 1 Stock Is the Indispensable Backbone of the $1.8 Trillion Space Economy — and It’s Not SpaceX](https://longbridge.com/en/news/289356019.md)
- [Don't buy SpaceX stock at IPO without reading this first](https://longbridge.com/en/news/289128617.md)
- [Wait for the hype to come out of SpaceX before buying, says Mariner Wealth's Jeff Krumpelman](https://longbridge.com/en/news/289504457.md)
- [11:45 ETInventHelp Inventor Develops Temporarily Seal for a Leaking Pipe (OCC-1819)](https://longbridge.com/en/news/289489220.md)
- [100 days of the Iran war: How global markets and the economy have been affected, in charts](https://longbridge.com/en/news/288948610.md)